Extravasational side effects of cytotoxic drugs: A preventable catastrophe

Indian Journal of Plastic Surgery

Volumn 41, Issue 2, 2008, Pages 145-150

  Thakur, Jagdeep ^a   Chauhan, C G S ^a   Diwana, Vijay ^a   Chauhan, Dayal ^a   Thakur, Anamika ^a  

^a INDIRA GANDHI MEDICAL COLLEGE   (India)

Author keywords

Cytotoxic; Drugs; Extravasation; Prevention; Side effects

Indexed keywords

EID: 58749117233     PISSN: 09700358     EISSN: 1998376X     Source Type: Journal    
DOI: 10.4103/0970-0358.44923     Document Type: Article

References (37)

1. Bertelli G. Prevention and management of extravasation of cytotoxic drugs. Drug Safety 1995;12:245-55.
2. Dorr RT. Antidotes to vesicant chemotherapy extravasations. Blood Rev 1990;4:41-60.
3. Burd DAR, Santis G, Milward TM. Severe extravasation injury: An avoidable iatrogenic disaster? BMJ 1985;290:1579-80.
4. Upton J, Mulliken JB, Murray JE. Major intravenous extravasation injuries. Am J Surg 1979;137:497-506.
5. Chen JL, O'Shea M. Extravasation injury associated with low dose dopamine. Ann Pharmacother 1998;32:545-8.
6. Vanwijk R, Lengele B. Liposuction as a help for radiologists: Technical note. Ann Chir Plast Esthet 1994;72:702-4.
7. Schrijvers DL. Extravasation: A dreaded complication of chemotherapy. Ann Oncol 2003;14:iii26-30.
8. Herrington JD, Figueroa JA. Severe necrosis due to paclitaxel extravasation. Pharmacotherapy 1997;17:163-5.
9. Olver IN, Aisner J, Hament A, Buchanan L, Bishop JF, Kaplan RS. A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 1988;6:1732-5.
10. Alberts DS, Dorr RT. Case report: Topical DMSO for Mitomycin C induced skin ulceration. Oncol Nurs Forum 1991;18:693-5.
11. Bertelli G, Dini D, Forno GB, Gozza A, Silvestro S, Venturini M, et al. Hyaluronidase as an antidote to extravasation to vinca alkaloids. J Cancer Res Clin Oncol 1994;120:505-6.
12. Bertelli G, Gozza A, Forno GB, Vidili MG, Silvestro S, Venturini M, et al. Topical dimethyl sulfoxide for the prevention of soft tissue injury after extravasation of vesicant drugs: A prospective clinical study. J Clin Oncol 1995;13:2851-5.
13. Dissa JJ, Chang RR, Mucci SJ, Goldberg NH. Prevention of adriamycin-induced -full thickness skin loss using Hyaluronidase infiltration. Plast Reconstr Surg 1998;101:370-4.
14. Langer SW, Sehested M, Jensen PB. Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res 2000;6:3680-6.
15. Langer SW, Sehested M, Jensen PB, Buter J, Giaccone G. Dexrazoxane in anthracycline extravasation. J Clin Oncol 2000;18:3064.
16. Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol 2004;15:858-62.
17. Mouridsen HT, Langer SW, Buter J, Eidtmann H, Rosti G, de Wit M, et al. Treatment of anthracycline extravasation with Savene (dexrazoxane): Results from two prospective clinical multicentre studies. Ann Oncol 2007;18:546-50.
18. Scuderi N, Onesti MG. Antitumour agents: Extravasation, management and surgical treatment. Ann Plast Surg 1994;32:39-44.
19. Langer SW, Thougaard AV, Sehested M, Jensen PB. Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. Cancer Chemother Pharmacol 2006;57:125-8.
20. Gault DT. Extravsation injuries. Br J Plast Surg 1993;46:91-6.
21. Steinmann G, Charpentier C, O'Neill TM, Bouaziz H, Mertes PM. Liposuction and extravasation injuries in ICU. Br J Anaesth 2005;95:355-7.
22. Hankin FM, Louis DS. Surgical management of doxorubicin (adriamycin) extravasation. J Pediatr Orthop 1984;4:96-9.
23. Heitmann C, Durmus C, Ingianni G. Surgical management after doxorubicin and epirubicin extravasation. J Hand Surg Br 1998;23:666-8.
24. Andersonn AP, Dahlstrom KK. Clinical results after doxorubicin extravasation treated with excision guided by fluorescence microscopy. Eur J Cancer 1993;29A:1712-4.
25. Larson DL. What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg 1985;75:397-405.
26. von Heimburg D, Pallua N. Early and late treatment of iatrogenic injection damage (article in German). Chirurg 1998;69:1378-82.
27. Loth TS, Eversmann WW Jr. Extravasation injuries in upper extremity. Clin Orthop Relat Res 1991;272:248-54.
28. Khan MS, Homes JD. Reducing the morbidity from extravasation injuries. Ann Plast Surg 2002;48:628-32.
29. Rudolph R, Larson DL. Aetiology and treatment of chemotherapeutic agent extravasation injuries: A review. J Clin Oncol 1987;5:1116-26.
30. Tsavaris NB, Karagiaouris P, Tzannou I, Komitsopoulou P, Bacoyiannis C, Karabellis A, et al. Conservative approach to the treatment of chemotherapy-induced extravasation. J Dermatol Surg Oncol 1990;16:519-22.
31. Shenaq SM, Abbase EH, Friedman JD. Soft-tissue reconstruction following extravasation of chemotherapeutic agents. Surg Oncol Clin N Am 1996;5:825-45
32. Cedidi C, Hierner R, Berger A. Plastic surgical management in tissue extravasation of cytotoxic agents in the upper extremity. Eur J Med Res 2001;6:309-14.
33. Langstein HN, Duman H, Seeling D, Butler CE, Evans GR. Retrospective study of the management of chemotherapeutic extravasation injury. Ann Plast Surg 2002;49:369-74.
34. Eroglu E, Sari A, Altuntas I, Delibas N, Candir C, Agalar F. The effect of GM-CSF (granulocyte macrophage colony stimulating factor) on doxorubicin-induced tissue necrosis and wound healing. Indian J Cancer 2000;37:153-7.
35. Ulutin HC, Guden M, Dede M, Pak Y. Comparison of granulocyte-colony stimulating factor and granulocyte macrophage-colony stimulating factor in the treatment of chemotherapy extravasation ulcers. Eur J Gynaecol Oncol 2000;21:613-5.
36. Vargel I, Erdem A, Ertoy D. Effects of growth factors on doxorubicin-induced skin necrosis: Documentation of histomorphological alteration and early treatment by GM-CSF and G-CSF. Ann Plast Surg 2002;49:646-53.
37. Schneider SM, Distelhorst CW. Chemotherapy induced emergencies. Semin Oncol 1989;16:572-8.